Uni Eropa - Sloven - EMA (European Medicines Agency)

zoetis belgium sa - prašičev circovirus cepivo (inaktivirano, rekombinantne) - immunologicals for suidae, inactivated viral vaccines - prašičev (za pitanje) - za aktivno imunizacijo prašičev od 3 tednov starosti proti prašičji circovirus tipa 2 (pcv2) za zmanjšanje virusne obremenitve) v krvi in lymphoid tkiv in odpade odpuščanje, ki jih povzroča okužba z pcv2.

Uni Eropa - Sloven - EMA (European Medicines Agency)

intervet international b.v. - v živo myxoma vectored rhd virus sev 009, Živo myxoma vectored rhd virus sev mk1899 - immunologicals za leporidae - kunci - za aktivno imunizacijo kuncev od 5. tedna starosti dalje za zmanjšanje umrljivosti in kliničnih znakov miksomatoze in zajec hemoragične bolezni (rhd), ki jih povzročajo klasični rhd virus (rhdv1) in rhd tipa 2 virus (rhdv2).

Uni Eropa - Sloven - EMA (European Medicines Agency)

laboratorios hipra, s.a. - v živo vidni nalezljive bursal bolezni virus (ibdv), sev 1052 - immunologicals za aves, domačo kokošjo, Živo virusna cepiva, ptic nalezljive bursal bolezni virus (bolezni gumboro) - chicken; embryonated chicken eggs - za aktivno imunizacijo 1-dan-stare pitovnih piščancev in embryonated pitovnih kokošja jajca za zmanjšanje kliničnih znakov bolezni in poškodb od bursa od fabricius, ki jih povzročajo zelo virulentni aviarne nalezljive bursal bolezni, okužbe z virusom.

Uni Eropa - Sloven - EMA (European Medicines Agency)

ceva-phylaxia co. ltd. - live recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus (rfp-lt) and avian encephalomyelitis virus, strain calnek 1143 (ae) - immunologicals for aves, live viral vaccines, domestic fowl - piščanec - for active immunisation of chickens of 8 to 13 weeks of age in order to reduce the skin lesions due to fowlpox, to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis and to prevent egg production losses due to avian encephalomyelitis.

Uni Eropa - Sloven - EMA (European Medicines Agency)

fatro s.p.a - rabbit hemorrhagic disease virus 2 vp1ab, rabbit hemorrhagic disease virus vp1a - immunologicals za leporidae - kunci - for active immunisation of rabbits from the age of 28 days to reduce mortality, infection, clinical signs and organ lesions of rabbit haemorrhagic disease caused by rhdv1 and rhdv2.

Uni Eropa - Sloven - EMA (European Medicines Agency)

zoetis belgium sa - synthetic peptide analogue of gnrf conjugated to diptheria toxoid - imunologija za suidae - male pigs (from 8 weeks of age); female pigs (from 14 weeks of age) - male pigs:induction of antibodies against gnrf to produce a temporary immunological suppression of testicular function. for use as an alternative to physical castration for the reduction of boar taint caused by the key boar taint compound androstenone, in entire male pigs following the onset of puberty. drugi ključni dejavnik merjasca taint, skatole, se lahko tudi zmanjša kot posredni učinek. agresiven in spolne (montaža) vedenje so zmanjšane tudi. female pigs:induction of antibodies against gnrf to produce a temporary immunological suppression of ovarian function (suppression of oestrus) in order to reduce the incidence of unwanted pregnancies in gilts intended for slaughter, and to reduce the associated sexual behaviour (standing oestrus).

Uni Eropa - Sloven - EMA (European Medicines Agency)

zoetis belgium sa - inaktivirano bolezni modrikastega jezika virus, serotip 1, sev btv-1/alg2006/01 e1 ns, inaktivirano bolezni modrikastega jezika virus, serotip 8, sev btv-8/bel2006/02 - bolezen modrikastega jezika virus, immunologicals, immunologicals za bovidae, govedo, inaktivirano virusna cepiva - govedo - aktivna imunizacija goveda od 3 mesecev starosti za preprečevanje viremije, ki jo povzroča virus modrikastega jezika (btv), serotipi 1 in 8. * (kolesarska vrednost (ct) ≥ 36 z validirano metodo rt-pcr, ki nima prisotnosti virusnega genoma).

Uni Eropa - Sloven - EMA (European Medicines Agency)

instituto grifols s.a. - Človekove normalno imunoglobulina - mucocutaneous lymph node syndrome; guillain-barre syndrome; bone marrow transplantation; purpura, thrombocytopenic, idiopathic; immunologic deficiency syndromes - imunski sera in imunoglobulini, - replacement therapy in adults, children and adolescents (0-18 years) in: , primary immunodeficiency syndromes with impaired antibody production;, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed;, hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation;, hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (hsct);, congenital aids with recurrent bacterial infections. , immunomodulation in adults, children and adolescents (0-18 years) in: , primary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, guillain barré syndrome;, kawasaki disease.

Uni Eropa - Sloven - EMA (European Medicines Agency)

mérial - bolezen modrikastega jezika-virus serotip-2 antigen, bolezen modrikastega jezika-virus serotip-4 antigen - bolezen modrikastega jezika virus, inaktivirano virusna cepiva, immunologicals za ovidae - ovce - aktivna imunizacija ovac za preprečevanje viremije in zmanjšanje kliničnih znakov, ki jih povzročajo serotipi 2 in 4 virusa bolezni modrikastega jezika.

Uni Eropa - Sloven - EMA (European Medicines Agency)

zoetis belgium sa - live recombinant e2 gene-deleted bovine viral diarrhoea virus containing classical swine fever virus e2 gene (cp7_e2alf) - live viral vaccines, immunologicals for suidae - prašiči - za aktivno imunizacijo prašičev od 7 tednov dalje za preprečevanje smrtnosti in zmanjšanje okužb in bolezni, ki jih povzroča virus klasične prašičje kuge (csfv). onset of immunity: 14 days after vaccinationduration of immunity: at least 6 months after vaccinationfor active immunisation of breeding females to reduce transplacental infection caused by csfv. onset of immunity: 21 days after vaccinationduration of immunity has not been demonstrated.